Literature DB >> 21447598

Expression of tumor-promoting Cyr61 is regulated by hTRA2-β1 and acidosis.

Marc Hirschfeld1, Markus Jaeger, Emanuele Buratti, Cristiana Stuani, Johannes Grueneisen, Gerald Gitsch, Elmar Stickeler.   

Abstract

The matricellular protein Cysteine rich 61 (Cyr61) displays a remarkable diversity of multiple cellular functions involved in significant physiologic and pathologic processes. Cyr61 is known as an important player in tumor progression, promoting neovascularization and metastasis. Our prior investigations elucidated an oxygen-dependent Cyr61 alternative splicing process characterized by retention of its intron 3, regulating its biological function in a hypoxia-driven on/off switch mechanism. In this work, we identified extracellular acidosis as a potent inducer for altered Cyr61 alternative splicing pattern regulating Cyr61 expression. Intriguingly, splicing factor hTRA2-beta1 displayed an opposite effect on Cyr61 expression. Nuclear hTRA2-beta1 protein expression was found markedly reduced under acidic conditions. In keeping with these conclusions, we show that hTRA2-beta1 can specifically bind a 'GAAG' motif in Cyr61 exon 3 RNA, that the splicing factor displays acidosis-dependent protein localization in cellular compartments, and shRNA-mediated hTRA2-beta1 knock-down triggers the same effects on Cyr61 alternative splicing like acidosis or hypoxia. Our findings strongly support the hypothesis of a specific regulation of Cyr61 expression by hTRA2-beta1.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21447598     DOI: 10.1093/hmg/ddr128

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  6 in total

Review 1.  Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets.

Authors:  Joon-Il Jun; Lester F Lau
Journal:  Nat Rev Drug Discov       Date:  2011-12-01       Impact factor: 84.694

2.  Clinical relevance of Cyr61 expression in patients with hormone-dependent breast cancer.

Authors:  Sebastian Mayer; Thalia Erbes; Sylvia Timme-Bronsert; Markus Jaeger; Gerta Rücker; Franciska Kuf; Elmar Stickeler; Gerald Gitsch; Marc Hirschfeld
Journal:  Oncol Lett       Date:  2017-06-16       Impact factor: 2.967

3.  Differential Degradation of TRA2A and PYCR2 Mediated by Ubiquitin E3 Ligase E4B.

Authors:  Yao Lu; Bo Jiang; Kangli Peng; Shasha Li; Xiangnan Liu; Bufan Wang; Yuntian Chen; Tiepeng Wang; Bo Zhao
Journal:  Front Cell Dev Biol       Date:  2022-05-20

Review 4.  Role of pseudoexons and pseudointrons in human cancer.

Authors:  Maurizio Romano; Emanuele Buratti; Diana Baralle
Journal:  Int J Cell Biol       Date:  2013-09-24

5.  Targeting the splicing factor NONO inhibits GBM progression through GPX1 intron retention.

Authors:  Xu Wang; Mingzhi Han; Shuai Wang; Yanfei Sun; Wenbo Zhao; Zhiyi Xue; Xiangjun Liang; Bin Huang; Gang Li; Anjing Chen; Xingang Li; Jian Wang
Journal:  Theranostics       Date:  2022-07-11       Impact factor: 11.600

6.  Mesenchymal stem cell contact promotes CCN1 splicing and transcription in myeloma cells.

Authors:  Julia Dotterweich; Regina Ebert; Sabrina Kraus; Robert J Tower; Franz Jakob; Norbert Schütze
Journal:  Cell Commun Signal       Date:  2014-06-25       Impact factor: 5.712

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.